FDA surprised observers by convening an advisory meeting for donanemab instead of quick approval, highlighting concerns over efficacy in specific Alzheimer's markers. Meeting resulted positively, indicating strong data standard.
Neurologist David Knopman notes the positive outcome of the FDA advisory meeting on donanemab, indicating difficulty for objections due to data quality. Donanemab targets amyloid, a protein in Alzheimer's brains, slowing cognitive decline in trial participants.
[
add
]
[
|
|
...
]